Tremelimumab and durvalumab for advanced liver cancer with Child-Pugh B
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (HCC) that cannot be treated with local therapies or has spread.
- Your cirrhosis is classified as Child-Pugh B7 or B8.
- You are able to take care of yourself (ECOG 0 or 1) and weigh more than 66 pounds (30 kg).
- Your blood counts and liver/kidney function are within certain limits (e.g., platelets >60, bilirubin ≤3).
- You must not have received prior systemic therapy for your liver cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
This Phase 2 trial studies durvalumab and tremelimumab (immunotherapy medicines) in people with resectable early or intermediate-stage liver cancer (HCC). It aims to see how well these medicines work before/around the time of surgery, and whether they can improve outcomes.
This trial tests adding a targeted chemo infusion into the liver's main artery to two immunotherapy drugs for liver cancer. It may help patients whose cancer has spread within the liver and can't be removed by surgery.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
This trial tests a combination of two drugs, zanzalintinib and durvalumab, as a maintenance treatment for people with advanced liver cancer (hepatocellular cancer) that has not gotten worse after initial treatment with tremelimumab and durvalumab. The goal is to see if this combination can help keep the cancer from growing.
This Italian study follows patients with advanced liver cancer (hepatocellular carcinoma) who receive a combination immunotherapy treatment called STRIDE for the first time. The trial tracks how well the treatment works, how it affects quality of life, and its safety in people with moderate to severe liver disease.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.